Your browser doesn't support javascript.
loading
Association of COVID-19 with Rhino-Cerebral Mucormycosis: An Observational Study.
Agarwal, Varsha; Gupta, Ambika; Singh, Virendra; Jajodia, Neha; Popli, Harsha; Akilan, R.
Afiliação
  • Agarwal V; Dept. of Oral Medicine and Radiology, Post Graduate Institute of Dental Sciences, Room No. 11, Rohtak, 124001 India.
  • Gupta A; Dept. of Oral Medicine and Radiology, Post Graduate Institute of Dental Sciences, Room No. 11, Rohtak, 124001 India.
  • Singh V; Dept. Of Oral and Maxillofacial Surgery, Post Graduate Institute of Dental Sciences, Rohtak, India.
  • Jajodia N; Dept. Of Oral and Maxillofacial Surgery, Post Graduate Institute of Dental Sciences, Rohtak, India.
  • Popli H; Dept. of Oral Medicine and Radiology, Post Graduate Institute of Dental Sciences, Room No. 11, Rohtak, 124001 India.
  • Akilan R; Dept. Of Oral and Maxillofacial Surgery, Post Graduate Institute of Dental Sciences, Rohtak, India.
J Maxillofac Oral Surg ; 21(3): 990-994, 2022 Sep.
Article em En | MEDLINE | ID: mdl-34785873
ABSTRACT
Mucormycosis is becoming more common in patients infected with or recovering from COVID-19 under the current situation. However, there is a scarcity of research on a specific group of COVID-19 individuals who are predisposed to mucormycosis. As a result, a retrospective observational study was undertaken to assess the possible connection of mucormycosis with COVID-19. The goal was also to investigate the link between diabetes mellitus, mucormycosis and COVID-19. The occurrence and severity of the disease among the case records were assessed using signs and symptoms, investigations conducted during COVID-19, and serological test results. Patients were classified as previously known diabetics, recently diagnosed diabetics, or non-diabetics based on their history of pre-existing DM and HBA1c levels at the time of reporting for mucormycosis. The findings show that mild COVID-19-infected patients and non-diabetic patients have a high incidence of COVID-19-associated mucormycosis (CAM). As a result, all clinicians participating in the care of COVID-infected patients must be aware of the significant risk of secondary mucormycosis in the post-recovery phase, even in those with mild or moderate symptoms.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Observational_studies / Risk_factors_studies Idioma: En Revista: J Maxillofac Oral Surg Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Observational_studies / Risk_factors_studies Idioma: En Revista: J Maxillofac Oral Surg Ano de publicação: 2022 Tipo de documento: Article